The world’s largest vaccine manufacturer is facing a deadly shortage of COVID-19 doses. From planning to procurement and pricing, everything went wrong.
Murali Neelakantan, a former global general counsel for pharma heavyweights who has worked extensively on issues related to the intersection of healthcare and law, dissects the crisis – from IPR to procurement and production to pricing – for All Indians Matter.
